| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Revenue | 13,074 | 12,083 | ||
| Cost of sales | 3,147 | 3,214 | ||
| Gross profit | 9,927 | 8,869 | ||
| Research and development | 4,445 | 4,160 | ||
| Sales and marketing | 9,610 | 7,869 | ||
| General and administrative | 4,907 | 3,342 | ||
| Total operating expenses | 18,962 | 15,371 | ||
| Loss from operations | -9,035 | -6,502 | ||
| Interest expense | 380 | 363 | ||
| Interest income | 954 | 336 | ||
| Change in fair value of warrant liabilities | 65 | 237 | ||
| Total other income (expense), net | 509 | -264 | ||
| Net loss | -8,526 | -6,766 | ||
| Deemed dividend to preferred stockholders | 0 | 0 | ||
| Net loss attributable to common stockholders | -8,526 | -6,766 | ||
| Earnings per share, basic | -0.4 | -1.47 | ||
| Earnings per share, diluted | -0.4 | -1.47 | ||
| Weighted average number of shares outstanding, basic | 21,081,330 | 4,589,717 | ||
| Weighted average number of shares outstanding, diluted | 21,081,330 | 4,589,717 | ||
CARLSMED, INC. (CARL)
CARLSMED, INC. (CARL)